Abstract

BackgroundTo examine the differences in menopausal hormone therapy (MHT) use and user profiles among women in Germany before and after the communication of the Women's Health Initiative (WHI) trial and other study results concerning the risks and benefits of MHT.MethodsCurrent MHT use was ascertained in two periodic German national health surveys conducted in 1997–1999 and 2003–2004. MHT prevalence and user profiles were assessed within each survey. The association of the survey period (2003–2004 vs. 1997–1999) with current MHT use was analyzed in weighted multivariable logistic regression (MLR) models, pooling data from both surveys.ResultsThe overall prevalence of current MHT use decreased by 40.2% from 16.9% of the sample in 1997–1999 to 10.1% in 2003–2004. The difference in prevalence between surveys varied with age decade with the smallest decreases among women 60–69 years of age (20.3% vs. 18.5%), compared to women of younger and older age groups (40–49: 10.7% vs. 3.9%; 50–59: 36.3% vs. 21.3%; 70–79: 5.7% vs. 3.2%). Variables independently associated with higher current MHT use in both health surveys included age category (curvilinear relationship with highest use among women 50–59 years) and residence in West vs. East Germany. A higher social status, lower body mass index, and more health-conscious behaviour were significantly associated with higher current MHT use in the 1997–1999 survey, but these associations were not found in the later survey. MLR analyses confirmed a significant decline in MHT use between the 1997–1999 and 2003–2004 surveys, however, the effect was modified by social status and was not significant among lowest social-status women.ConclusionCurrent MHT use considerably declined among women in Germany between the pre- and post-WHI era. A convergence of current MHT use among women of higher social status with pre-existing patterns of use among lower social-status women suggests that MHT in Germany is now less likely to be used for health promotion.

Highlights

  • To examine the differences in menopausal hormone therapy (MHT) use and user profiles among women in Germany before and after the communication of the Women's Health Initiative (WHI) trial and other study results concerning the risks and benefits of MHT

  • Main findings In this analysis of two German national health surveys conducted before and after the publication of EPT-WHI results, we found that the overall prevalence of current MHT use among women aged 40–79 years decreased by 40.2% from 16.9% of the sample in the 1997–1999 survey to 10.1% in the 2003–2004 survey

  • While neither we nor others can prove a direct relationship to the interim publication and media coverage of results from the EPT-WHI trial and other studies such as the Million Women Study, this is suggested by parallel developments in various countries

Read more

Summary

Introduction

To examine the differences in menopausal hormone therapy (MHT) use and user profiles among women in Germany before and after the communication of the Women's Health Initiative (WHI) trial and other study results concerning the risks and benefits of MHT. During the past two decades menopausal hormone therapy (MHT, the term used for both estrogen therapy and estrogen plus progestin therapy) has been widely proposed and prescribed for postmenopausal women, for the relief of menopausal symptoms, and for the prevention of cardiovascular diseases and osteoporosis in later life. Such advice to women was based on a wealth of supporting results from preclinical as well as observational clinical and epidemiological studies, confirmatory data from randomized clinical trials (RCTs) were still lacking or not based on hard clinical endpoints [1,2]. We have analyzed differences in the prevalence and correlates of current MHT use among women in Germany, based on data from two periodic national health surveys conducted in 1997–1999 and 2003–2004

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call